Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Рак печени (гепатоцеллюлярный)

Список литературы

  1. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ НМИРЦ Минздрава России, 2016. 250 с.
  2. AJCC cancer staging manual, eight edition. Springer International Publishing, 2017.
  3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69(1):182–236.
  4. Forner A., Reig M., Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301–14.
  5. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35–50.
  6. Vogel A., Cervantes A., Chau I. et al. Hepatocellular carcinoma: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv238–55.
  7. Marrero J.A., Kulik L.M., Sirlin C.B. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68(2):723–50.
  8. Terrault N.A., Bzowej N.H., Chang K.M. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261–83.
  9. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Available at: https://www.aasld.org/ sites/default/files/2019- 06/PracticeGuidelines-HCV-November2018.pdf.
  10. Waidely E., Al-Yuobi A.R., Bashammakh A.S. et al. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst 2016;141(1):36–44.
  11. Arrieta O., Cacho B., Morales-Espinosa D. et al. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007;7:28.
  12. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers, version 3.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
  13. Peng Y., Qi X., Guo X. Child–Pugh versus MELD Score for the assessment of prognosis in liver cirrhosis a systematic review and meta-analysis of observational studies. Medicine (Baltimore) 2016;95(8):e2877.
  14. Forner A., Vilana R., Ayuso C. et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97–104.
  15. Chou R., Cuevas C., Fu R. et al. Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 2015; 162:697–711.
  16. Lee Y.J., Lee J.M., Lee J.S. et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015;275:97–109.
  17. Cerny M., Chernyak V., Olivié D. et al. LI-RADS Ver 2018 Ancillary Features at MRI. Radiographics 2018;38(7):1973–2001.
  18. Chernyak V., Santillan C.S., Papadatos D. et al. LI-RADS® algorithm: CT and MRI. Abdom Radiol 2018;43(1):111–26.
  19. Ludwig D.R., Fraum T.J., Cannella R. et al. Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria. HPB (Oxford) 2019;28(6):pii: S1365- 182X(19)30525-8.
  20. Elsayes K.M., Kielar A.Z., Chernyak V. et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019;6:49–69.
  21. Katyal S., Oliver J.H., Peterson M.S. et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698–703.
  22. Natsuizaka M., Omura T., Akaike T. et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:1781–7.
  23. Stewart C.J., Coldewey J., Stewart I.S. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol 2002;55:93–7.
  24. Sangiovanni A., Manini M.A., Iavarone M. et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638–44.
  25. Intenzo C., Kim S., Lakhani P. Utility of FDG-PET/CT in Detecting Metastases from Hepatocellular Carcinoma. J Nucl Med 2017;58 Suppl 1:427.
  26. Marrero J.A., Fontana R.J., Barrat A. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707–15.
  27. Cillo U., Vitale A., Grigoletto F. et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723–31.
  28. Chen C.H., Hu F.C., Huang G.T. et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – analysis of 2010 Taiwanese patients. Eur J Cancer 2009;45:1630–9.
  29. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.
  30. Truty M.J., Vauthey J.-N. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol 2010;17:1219– 25.
  31. Pawlik T.M., Poon R.T., Abdalla E.K. et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450–7.
  32. Chok K.S., Ng K.K., Poon R.T. et al. Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma. Br J Surg 2009;96:81–7.
  33. Ribero D., Curley S.A., Imamura H. et al. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol 2008;15:986–92.
  34. Berzigotti A., Reig M., Abraldes J.G. et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 2015;61:526–36.
  35. Fujiki M., Aucejo F., Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int 2011;31:1081–9.
  36. Majno P., Giostra E., Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials? Liver Transpl 2007;13:S27–35.
  37. Yin J., Li N., Han Y. et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013;31(29):3647–55.
  38. Huang G., Lau W.Y., Wang Z.G. et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg 2015;261(1):56–66.
  39. Lencioni R.A., Allgaier H.P., Cioni D. et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235–40.
  40. Lin S.M., Lin C.J., Lin C.C. et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151–6.
  41. Cho Y.K., Kim J.K., Kim M.Y. et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453–9.
  42. Bruix J., Takayama T., Mazzaferro V. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344–54.
  43. Robbins J.R., Schmid R.K., Hammad A.Y. et al. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. Cancer Med 2019;8(3):928–38.
  44. Rand T., Loewe C., Schoder M. et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol 2005;28:313–8.
  45. Bonomo G., Pedicini V., Monfardini L. et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol 2010;33:552–9.
  46. Llovet J.M., Real M.I., Montana X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–9.
  47. Affonso BB, Galastri FL, da Motta Leal Filho JM et al., Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging World J Gastroenterol. 2019 Oct 7;25(37):5687-5701.
  48. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate- stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212–220.
  49. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 2014;11:525–535
  50. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60.
  51. Cerrito L, Annicchiarico BE, Iezzi R. et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers, World J Gastroenterol. 2019 Aug 21;25(31):4360-4382.
  52. Chino F, Stephens SJ, Choi SS, et al. The role of external beam radiotherapy in the treatment of hepatocellular cancer. Cancer. 2018 Sep 1;124(17):3476-3489.
  53. Llovet J.M., Ricci S., Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
  54. Cheng A.L., Kang Y.K., Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
  55. Bruix J., Raoul J.-L., Sherman M. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821–9.
  56. Kudo M., Finn R.S., Qin S. et al. Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 trial. Lancet 2018;391:1163–73.
  57. Bruix J., Qin S., Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56–66.
  58. Abou-Alfa GK, Meyer T, Cheng A-L, M.D., et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379:54-63
  59. El-Khoueiry A.B., Sangro B., Yau T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492–502.
  60. Finn R.S., Ryoo B.-Y., Merle P. et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2019;37(15 Suppl):4004.
  61. Qin S., Bai Y., Lim H.Y. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:3501–8.
  62. Zaanan A; Williet N; Hebbar M; et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013; 58(1):81-8
  63. Tovoli F, Renzulli M, Granito A, Golfieri R & Bolondi L. Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepat. Oncol. (2017) 4(4), 129–137
  64. Paolo A, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis J of Hepatology, Vol 69, Issue 2, 406 – 460
  65. Luther A., Gabriel J., Watson R.P., Francis N.K. The impact of total body prehabilitation on post- operative outcomes after major abdominal surgery: a systematic review. World J Surg 2018;42(9):2781–91.
  66. Arends J., Bachmann P., Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36:11–48.
  67. Souza Possa S., Braga Amador C. Meira Costa A. et al. Implementation of a guideline for physical therapy in the postoperative period of upper abdominal surgery reduces the incidence of atelectasis and length of hospital stay. Rev Port Pneumol 2014;20(2):69–77.
  68. Lewis L.K., Williams M.T., Olds T.S. The active cycle of breathing technique: a systematic review and meta-analysis. Respir Med 2012;106(2):155–72.
  69. Cho I., Son Y., Song S. et al. Feasibility and effects of a postoperative recovery exercise program developed specifically for gastric cancer patients (PREP-GC) undergoing minimally invasive gastrectomy. J Gastric Cancer 2018;18(2):118–33.
  70. Hunter E.G., Baltisberger J. Functional outcomes by age for inpatient cancer rehabilitation: a retrospective chart review. J Appl Gerontol 2013;32(4):443–56.
  71. Грушина Т.И. Реабилитация в онкологии: физиотерапия. М.: ГЭОТАР-Медиа, 2006. 240 с.
  72. Ajani J.A., D"Amico T.A., Almhanna K. et al. Gastric Cancer, Version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016;14(10):1286–312.
  73. Bland K.A., Zadravec K., Landry T. et al. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol 2019;136:79–85.
  74. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289–304.
  75. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018;10(Suppl 35):S4391–9.
  76. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012;30(15 Suppl):9019.
  77. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2016;38(2):85–94.
  78. Kumar A, Ahuja CK, Vyas S, et al. Hepatic arteriovenous fistulae: role of interventional radiology. Dig Dis Sci 2012;57:2703–12.
  79. Wu H, Zhao W, Zhang J, Han J, Liu S. Clinical characteristics of hepatic arterioportal shunts associated with hepatocellular carcinoma. BMC Gastroenterol. 2018 Nov 12;18(1):174. doi: 10.1186/s12876-018-0899-3.
  80. Kim, J. H., Sinn, D. H., Kim, K., et al. Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Digestive Diseases and Sciences, (2016). 61(11), 3354–3362. doi:10.1007/s10620-016-4255-6
  81. Finkelmeier F, Waidmann O. & Trojan J: Nivolumab for the treatment of hepatocellular carcinoma, Expert Review of Anticancer Therapy 2018, DOI: 10.1080/14737140.2018.1535315
  82. Zhao X, Ivaturi V, Gopalakrishnan M, et al. A model-based exposure-response (ER) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types. Cancer Res. 2017 Jul; 77 Suppl:13.
  83. Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000;89:750-6.
  84. Zaanan A, Williet N, Hebbar M, Dabakuyo TS, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013 Jan; 58(1):81-8. doi: 10.1016/j.jhep.2012.09.006.
  85. Chakrabarti , Kommalapati A, Tella S. H,et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Clin Oncol 2019 37:4_suppl, 393-393
  86. Chieh Kow, A. Transplantation versus liver resection in patients with hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2019, vol 4, number 0. doi: 10.21037/tgh.2019.05.06

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*